Revista espanola de medicina nuclear e imagen molecular最新文献

{"title":"18F-FDG PET-CT in multifocal hydatidosis","authors":"G. Molina-Mendoza, M. Talavera Rubio, F. López-Bermejo García, J. Gatón Ramírez, V. Poblete García","doi":"10.1016/j.remnie.2025.500176","DOIUrl":"10.1016/j.remnie.2025.500176","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 5","pages":"Article 500176"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT in suspected primary CNS lymphoma: Systemic involvement assessment and biopsy guidance","authors":"P. Dauden-Onate , C.G. Wakfie-Corieh , R.M. Couto-Caro , M.L. Suarez-Solis , C. Benavente-Cuesta , M.N. Cabrera-Martín","doi":"10.1016/j.remnie.2025.500140","DOIUrl":"10.1016/j.remnie.2025.500140","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 5","pages":"Article 500140"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erdheim Chester disease: Diagnosis and follow-up on PET/CT [18F]FDG","authors":"S. López Puche , J.G. Villanueva Curto , P. García-Talavera San Miguel , J.A. Badell Martínez , S. Rama Alonso , M.P. Tamayo Alonso","doi":"10.1016/j.remnie.2025.500179","DOIUrl":"10.1016/j.remnie.2025.500179","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 5","pages":"Article 500179"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing prostate cancer treatment: PSMA-targeted therapy in modern therapeutics","authors":"A. Ricaurte-Fajardo ,&nbsp;V. Marulanda-Corzo ,&nbsp;S. Ruder ,&nbsp;D.R. Cardoza-Ochoa ,&nbsp;C.E. Granados ,&nbsp;D. Yadav ,&nbsp;D. López-Delgado ,&nbsp;M. Fatima ,&nbsp;S. Dutruel ,&nbsp;E. O’Dwyer ,&nbsp;J.R. Osborne ,&nbsp;S.T. Tagawa ,&nbsp;S. Huicochea Castellanos","doi":"10.1016/j.remnie.2025.500162","DOIUrl":"10.1016/j.remnie.2025.500162","url":null,"abstract":"<div><div><span><span>Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has reshaped the treatment landscape for metastatic castration-resistant </span>prostate cancer (mCRPC), offering new therapeutic possibilities beyond conventional approaches. Among the most promising strategies is lutetium-177 PSMA-617, which has shown significant benefits in </span>overall survival<span> and durable PSA<span> responses, as demonstrated in several clinical trials.</span></span></div><div><span>At the same time, the development of novel radionuclides<span> such as actinium-225 has opened the door to more potent treatments capable of overcoming prior resistance, particularly in patients previously exposed to beta emitters. The use of PSMA PET imaging and the identification of predictive biomarkers have helped refine patient selection, contributing to a more personalized approach. Comparative studies with agents like </span></span>cabazitaxel have further supported the safety and effectiveness of this strategy.</div><div>This article provides a critical overview of clinical advances in PSMA-targeted radionuclide therapy, examines emerging combination treatments, reviews the development of alpha-emitting agents, and highlights the role of personalized dosimetry<span><span> in clinical practice, underlining the growing importance of this therapeutic modality across different stages of </span>prostate cancer.</span></div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 5","pages":"Article 500162"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Evaluating the role of sarcopenia and [18F]FDG PET/CT parameters in prognosis of pancreatic ductal adenocarcinoma","authors":"D. Mut Surmeli","doi":"10.1016/j.remnie.2025.500125","DOIUrl":"10.1016/j.remnie.2025.500125","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500125"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare imaging features of adult chronic recurrent multifocal osteomyelitis on PET/CT","authors":"R. Luo ,&nbsp;W. Zhang ,&nbsp;A. Kuang,&nbsp;Y. Li","doi":"10.1016/j.remnie.2025.500121","DOIUrl":"10.1016/j.remnie.2025.500121","url":null,"abstract":"","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500121"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II","authors":"L. Sancho ,&nbsp;A. Roteta ,&nbsp;I. Torres ,&nbsp;M. de Arcocha ,&nbsp;R. Ramos ,&nbsp;M.L. Domínguez ,&nbsp;J.J. Rosales ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;en nombre del Grupo de Oncología de la SEMNim","doi":"10.1016/j.remnie.2025.500128","DOIUrl":"10.1016/j.remnie.2025.500128","url":null,"abstract":"<div><div>The state of the art and future perspectives of new radionuclides in Nuclear Medicine continue to evolve, driven by the development of isotopes with innovative applications in theragnostics.</div><div>In this second part of the continuing education series, the clinical and therapeutic applications of terbium, actinium, and bismuth are analyzed in depth. The use of the four terbium isotopes (terbium-149, terbium-152, terbium-155, and terbium-161) is described, offering a versatile system for both diagnosis and treatment due to their chemical similarity to lutetium-177, along with the challenges related to their production and availability. Additionally, actinium-225, a powerful alpha-emitting radionuclide, is reviewed for its growing role in Targeted Alpha Therapy (TAT), particularly in prostate cancer and neuroendocrine tumors. Finally, bismuth-213, derived from actinium-225, is analyzed for its short half-life, making it a viable option for localized and selective therapies.</div><div>Despite technical and production challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities in Nuclear Medicine.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500128"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of dosimetry and clinical variables in treatments of neuroendocrine tumours with [177Lu]Lu-DOTA-TATE","authors":"P. Mínguez Gabiña ,&nbsp;T. Monserrat Fuertes ,&nbsp;B. Santos Zorrozua ,&nbsp;A. Esteban Figueruelo ,&nbsp;M.A. Astudillo Sarmiento ,&nbsp;A. Peña Fuentes ,&nbsp;I. Vinagre Pérez ,&nbsp;E. Rodeño Ortiz de Zarate ,&nbsp;I.L. Fernández Tercero","doi":"10.1016/j.remnie.2024.500089","DOIUrl":"10.1016/j.remnie.2024.500089","url":null,"abstract":"<div><h3>Purpose</h3><div>The main objectives were to study differences between the first and the fourth cycle in dosimetry variables in patients treated for neuroendocrine tumours with four cycles of [¹⁷⁷Lu]Lu-DOTA-TATE, as well as to look for absorbed dose–effect correlations aiming to help individualise and optimise this therapy for future patients.</div></div><div><h3>Material and methods</h3><div>SPECT/CT based dosimetry of tumour lesions and kidneys was performed in the first and the fourth cycles of the [¹⁷⁷Lu]Lu-DOTA-TATE treatments for 17 patients from 2020 to 2023. Clinical variables of interest were collected in order to look for correlations with some dosimetry variables. Statistical analysis was performed using the R software.</div></div><div><h3>Results</h3><div>Regarding dosimetry variables, for lesions a significant decrease in absorbed dose, mass and initial activity between the first and fourth cycles was observed. For kidneys, a significant increase in absorbed dose was observed. Effective decay constants did not significantly change neither for lesions nor for kidneys. The relative decrease in lesion masses correlated with their total absorbed dose. Total absorbed doses to kidneys were well below the toxicity limits mostly used in this therapy. Relative decrease in lesion absorbed doses was significantly lower for tumour primary sites in ileum and jejunum compared to those in pancreas. Moreover, radiological response correlated with clinical response.</div></div><div><h3>Conclusions</h3><div>The results seem to indicate that the current treatment scheme could be optimised in order to obtain better treatment outcomes.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500089"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of [99mTc]Tc-DPD gated-SPECT-CT in the assessment of myocardial uptake patterns in transthyretin amyloidosis (TTR-CA)","authors":"F. Sebastián Palacid ,&nbsp;N. Álvarez Mena ,&nbsp;M. García Aragón ,&nbsp;R.d.C. Zambrano Infantino ,&nbsp;B.M. Jaramillo López ,&nbsp;J. Gómez Hidalgo ,&nbsp;B. Pérez López ,&nbsp;M.P. Redondo del Río ,&nbsp;R. Ruano Pérez","doi":"10.1016/j.remnie.2025.500081","DOIUrl":"10.1016/j.remnie.2025.500081","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the feasibility of identifying various distribution patterns of [^99mTc]Tc-DPD in patients with cardiac transthyretin amyloidosis using gated SPECT-CT.</div></div><div><h3>Materials and methods</h3><div>Gated SPECT-CT was performed in patients with a positive scintigraphy result for cardiac amyloidosis due to transthyretin (TTR-CA). Patients were categorized into several groups based on sex, degree of radiopharmaceutical uptake according to the Perugini’s visual scale and ventricular ejection fraction (LVEF). Cardiac polar maps were obtained using <em>Emory Cardiac Toolbox</em>™ software and scored by segments according to radiopharmaceutical uptake on a scale from 0 (no uptake) to 4 (very high uptake intensity). The Mann-Whitney U and Pearson's Chi-square statistical tests were employed to identify significant differences in distribution patterns according to the different variables under study.</div></div><div><h3>Results</h3><div>65 patients were evaluated. The gender variable determined the main statistically significant differences, highlighting distinct distribution patterns of the radiopharmaceutical at the cardiac level: while women showed lower accumulation of [^99mTc]Tc-DPD in the middle anterior (<em>p</em> <!-->=<!--> <!-->0.035) and basal anterior (<em>p</em> <!-->=<!--> <!-->0.001) segments, whereas men demonstrated higher accumulation in the basal anteroseptal (<em>p</em> <!-->=<!--> <!-->0.009) and basal inferoseptal (<em>p</em> <!-->=<!--> <!-->0.009) segments, and lower scores in the lateroapical segment (<em>p</em> <!-->=<!--> <!-->0.039).</div></div><div><h3>Conclusions</h3><div>Gated SPECT-CT is an essential tool for assessing the distribution pattern of [^99mTc]Tc-DPD of patients with TTR-CA, offering valuable insights into the pathophysiology of the disease.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500081"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical application of multimodality imaging for cardio-oncology in Latin America","authors":"Saurabh Malhotra ,&nbsp;Amalia Peix ,&nbsp;Claudia Gutierrez-Villamil ,&nbsp;Manuel Bazan ,&nbsp;Raffaele Giubbini ,&nbsp;Carla Cueva ,&nbsp;Enrique Estrada ,&nbsp;Diana Paez","doi":"10.1016/j.remnie.2024.500086","DOIUrl":"10.1016/j.remnie.2024.500086","url":null,"abstract":"<div><div>Latin America (LA) is one of the regions in the world with the highest levels of overweight, dyslipidemia, and diabetes mellitus, which, together with smoking and high blood pressure, are common risk factors for cardiovascular and oncological diseases. Chemotherapy (CT) and Radiotherapy (RT) have become two of the mainstays of treatment for several types of cancer. One of the most worrisome side effects generated by CT and RT is cardiotoxicity. There are several imaging techniques in cardiology that can inform the presence of underlying disease, but they differ in their availability and access to the masses, their accuracy and repeatability, all of which are important determinants of the applicability of these techniques in routine clinical practice. Thus, it is mandatory to promote a clinically effective and a cost-effective multimodality approach for risk stratification, diagnosis and management of cardiovascular diseases in oncologic patients. The purpose of this review is to inform cardiologists, oncologists, cardio-oncologists and imaging cardiologists on the cardiac imaging modalities that can be applied in patients with cancer, the differences among imaging techniques and recommendations on how to apply them in LA.</div></div>","PeriodicalId":94197,"journal":{"name":"Revista espanola de medicina nuclear e imagen molecular","volume":"44 3","pages":"Article 500086"},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}